Deals
Akorn Seeks Bankruptcy After Failed Takeover, FDA Warnings
- Generic drugmaker to put itself on bankruptcy auction block
- Major quality-control issues uncovered in Fresenius buyout bid
This article is for subscribers only.
Akorn Inc. sought bankruptcy protection from creditors after a series of deficiencies uncovered about its quality-control methods resulted in the collapse of rival Fresenius SA’s buyout of the generic drugmaker and subsequent warning letters from the U.S. Food and Drug Administration.
The Lake Forest, Illinois-based company listed as much as $10 billion of debt and $10 billion of assets in its Chapter 11 petition, filed on Wednesday in the Delaware bankruptcy court.